Dr. Edward I. Marcus, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,350
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Icahn School of Medicine at Mount Sinai
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
NY license 255287 · MI license 4301100076
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Sight Medical Doctors PLLC (115 clinicians)
- Sergiu Marcus MD PC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,350
- Services billed
- 109,611
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 17,286 | 81 |
| Imaging of retina | 3,768 | 1,367 |
| Injection of drug into eye | 2,009 | 535 |
| Injection, aflibercept, 1 mg | 1,878 | 237 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 1,470 | 64 |
| Destruction of growth of retina using a laser | 1,050 | 417 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 895 | 695 |
| Established patient problem focused exam of visual system | 856 | 683 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 819 | 47 |
| Established patient complete exam of visual system | 587 | 522 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in New York, NY | 154 |
| Ofloxacin Other prescribers in New York, NY | 124 |
| Atropine Sulfate | 123 |
| Dorzolamide Hcl Other prescribers in New York, NY | 90 |
| Latanoprost Other prescribers in New York, NY | 77 |
| Brimonidine Tartrate Other prescribers in New York, NY | 41 |
| Bromfenac Sodium | 35 |
| Timolol Maleate Other prescribers in New York, NY | 28 |
| Restasis (cyclosporine) Other prescribers in New York, NY | 22 |
| Difluprednate | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 215 payments worth $34,756 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $15,796 |
|---|---|
| Astellas Pharma US Inc | $10,155 |
| Apellis Pharmaceuticals, Inc. | $2,453 |
| Ani Pharmaceuticals, Inc. | $2,287 |
| Harrow Eye, LLC | $1,879 |
| Bausch & Lomb Americas Inc. | $682 |
| Mallinckrodt Hospital Products Inc. | $458 |
| AbbVie Inc. | $391 |
| Compensation for services other than consulting (speaking, faculty) | $23,694 |
|---|---|
| Food and Beverage | $5,650 |
| Consulting Fee | $2,720 |
| Honoraria | $1,575 |
| Travel and Lodging | $1,117 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $5,792 |
| Astellas Pharma US Inc Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $4,000 |
| Regeneron Healthcare Solutions, Inc. Jan 8, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $3,339 |
| Astellas Pharma US Inc Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $2,400 |
| Astellas Pharma US Inc Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $2,400 |
| Regeneron Healthcare Solutions, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,810 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,705 |
| Ani Pharmaceuticals, Inc. Oct 23, 2025 | Honoraria ILUVIEN · treatment of diabetic macular edema in patients who have been previously treated | $1,575 |
| Regeneron Healthcare Solutions, Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,448 |
| Apellis Pharmaceuticals, Inc. Oct 18, 2025 | Consulting Fee Syfovre · Ophthalmology | $1,443 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $2,400 |
| Regeneron Healthcare Solutions, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,810 |
| Regeneron Healthcare Solutions, Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,448 |
| Astellas Pharma US Inc Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $2,400 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,705 |
| Ani Pharmaceuticals, Inc. Oct 23, 2025 | Honoraria ILUVIEN · treatment of diabetic macular edema in patients who have been previously treated | $1,575 |
| Apellis Pharmaceuticals, Inc. Oct 18, 2025 | Consulting Fee Syfovre · Ophthalmology | $1,443 |
| Astellas Pharma US Inc Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $4,000 |
| Harrow Eye, LLC Jun 5, 2025 | Consulting Fee TRIESENCE · OPTOMETRY | $700 |
| Astellas Pharma US Inc May 29, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $800 |
| Regeneron Healthcare Solutions, Inc. May 21, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to LANCASTER, PA · in-kind | $835 |
| Apellis Pharmaceuticals, Inc. May 21, 2025 | Consulting Fee Syfovre · Ophthalmology | $577 |
| Regeneron Healthcare Solutions, Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $5,792 |
| Regeneron Healthcare Solutions, Inc. May 6, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to LANCASTER, PA · in-kind | $56.00 |
| Regeneron Healthcare Solutions, Inc. Feb 11, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to BROOKLYN, NY · in-kind | $226 |
| Regeneron Healthcare Solutions, Inc. Jan 8, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $3,339 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $31,438 in research payments for these studies, mostly to the institutions running them.
- A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular…
Astellas Pharma Global Development - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.